Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Generic, brand name and therapeutic class of product
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

3 evidence topics · 2 sources

Manufacturer: Outlook Therapeutics

“LYTENAVA™ (bevacizumab-vikg) Manufactured by: LYTENAVA is a trademark of Outlook Therapeutics, Inc. Outlook Therapeutics, Inc. ©2026 Outlook Therapeutics Inc. 111 S. Wood Ave, Unit #100 Iselin, NJ 08830 U.S. U.S. License No.: 2292” (opens the prescribing information at this quote)

Generic and brand names, therapeutic class

“LYTENAVA™ (bevacizumab-vikg) injection, for intravitreal use” (opens the prescribing information at this quote)
“LYTENAVA is a vascular endothelial growth factor (VEGF) inhibitor” (opens the prescribing information at this quote)
“LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).” (opens the prescribing information at this quote)

Development code name and prior identity

“ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development as an intravitreal injection for the treatment of wet AMD and other retinal diseases.” (opens the source at this quote in a new tab)